Revised BE Guidance on Paliperidone Palmitate
Federal Register Notice: FDA is making available a revised document: Draft Guidance on Paliperidone Palmitate. The recommendations provide specific guidance on the design of bioequivalence studies to support ANDAs for paliperidone palmitate extended-release injectable suspension. To download the guidance, click here. To view this notice, click here.